Clinical trials
Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials
Below are recruiting relapsed or refractory multiple myeloma (rrmm) clinical trials, each written for real people, not researchers. We’re tracking 1,258 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07319676RecruitingPhase 1/Phase 2
Targeted T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
Singapore, SingaporeAges 10–80 - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT07328373Recruiting
Depression Relapse Predictors Study
This trial looks at brain and genetic markers to understand why depression returns. It is for people with major depression who are not currently taking medication.
IstanbulAges 18–65 - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT07333677RecruitingEarly Phase 1
Testing CAR-T therapy for severe graves' disease
This early-phase trial tests a new type of treatment called CAR-T cells (special immune cells made in a lab) to target and calm down the overactive immune system in people with severe Graves' disease that hasn't improved with standard medicines. It may offer a new option for those who have been on treatment for years or have had multiple relapses.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Palo Alto, CaliforniaAges 18–75 - NCT07638553RecruitingPhase 3
Psilocybin to prevent alcohol relapse with depression
This study tests whether psilocybin (a psychedelic compound) can help people with severe alcohol use disorder stay sober longer, especially if they also have depression. Participants receive guided psilocybin sessions alongside counseling to reduce the risk of returning to heavy drinking.
BayonneAges 18 years+ - NCT07347171RecruitingPhase 1
Testing CG009301 for blood cancers that returned or didn't respond
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
NanchangAges 18–75 - NCT07360886Recruiting
Early detection of brain conditions in active drivers
This study looks at how well doctors can spot early signs of certain brain conditions in people who drive. You may join if you have a valid license, are between 18 and 85, and have one of the neurological diagnoses the study is focusing on.
Olomouc, Olomouc RegionAges 18–85 - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT07374029RecruitingPhase 1
T cell therapy with vaccine, decitabine, and venetoclax in AML
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
Boston, MassachusettsAges Any age - NCT01269853RecruitingPhase 1/Phase 2
Bevacizumab directly into brain arteries for recurrent brain tumors
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
New York, New YorkAges 18 years+ - NCT02917083RecruitingPhase 1
CD30 CAR T cell treatment for hard-to-treat lymphomas
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
Houston, TexasAges 12–75 - NCT02918188RecruitingPhase 2
Hydrogen therapy for steroid-resistant graft-versus-host disease
This Phase 2 study tests whether hydrogen therapy can improve symptoms in people with chronic graft-versus-host disease (cGVHD) who cannot tolerate steroid treatment. If steroids aren’t working or can’t be used, this trial may offer an alternative approach to help control the illness.
Beijing, Beijing MunicipalityAges Up to 65 years - NCT07404332RecruitingPhase 1
Combination therapy for tumors resistant to immunotherapy
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
Iowa City, IowaAges 18–99 - NCT07453095RecruitingPhase 2
Glofitamab for mantle cell lymphoma after CAR T-cell therapy
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
AlessandriaAges 18 years+ - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT06432465Recruiting
Brain stimulation to help prevent opioid relapse
This study uses a type of brain stimulation called tDCS (transcranial direct current stimulation) to see if it can help people who have recently started medication for opioid dependence (buprenorphine or methadone) stay on track and avoid relapse. The treatment is non-invasive and involves a mild electrical current applied to the scalp.
Providence, Rhode IslandAges 21–60 - NCT07673354Enrolling by invitation
Spinal cord stimulation at home for hand and arm function in MS
This trial tests if gentle electrical stimulation can help improve hand and arm function in people with multiple sclerosis. You will use a small device at home with support from a caregiver.
Seattle, WashingtonAges 18–70 - NCT07524231Recruiting
Laughter Yoga Effects on Health and Well-being
This study tests whether laughter yoga—guided exercises that combine laughter with breathing—can improve health outcomes. Researchers will measure how it affects participants' physical and mental well-being over time.
ElâzığAges 18 years+ - NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07537738Recruiting
Blood test to predict outcomes in MLL acute myeloid leukemia
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
BeijingAges 6–60 - NCT07539727Recruiting
Intestinal ultrasound to predict Crohn's disease flare-ups
This study tests whether a special ultrasound of the intestines can predict when Crohn's disease will flare up again in patients whose disease is currently well-controlled. If successful, doctors could catch flare-ups earlier and adjust treatment before symptoms worsen.
Guangzhou, GuangdongAges 18–70
Hear when a new Relapsed or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma (rrmm)?
- Yes. Clin2 currently lists 1,258 recruiting relapsed or refractory multiple myeloma (rrmm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma (rrmm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma (rrmm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.